Correlation between miR-222 and uterine cancer and its prognostic value

XIUJUAN NIE and HAILI TIAN

Department of Obstetrics and Gynecology, Dongying People's Hospital, Dongying, Shandong 257091, P.R. China

Received November 29, 2017; Accepted May 17, 2018

DOI: 10.3892/ol.2018.8815

Abstract. Relationship between the expression of miR-222 and uterine cancer was investigated to explore its prognostic value. A total of 66 patients with uterine cancer diagnosed by pathological examination in Dongying People's Hospital were enrolled from March 2014 to October 2016. Uterine cancer and adjacent tissues were collected, and the expression of miR-222 in the tissues was detected by stem-loop RT-PCR. The relationship between miR-222 expression and various clinicopathological features of uterine cancer was analyzed. All the patients were followed up to record the survival conditions. The results revealed that stem-loop RT-PCR method could specifically amplify miR-222. The expression of miR-222 in uterine cancer tissues was significantly upregulated compared with that in adjacent tissues (p<0.05). The expression level of miR-222 was significantly increased with the increase of degree of tumor differentiation (p<0.05). The expression of miR-222 in uterine cancer tissue was not significantly correlated with patients' age, tumor size, gross tumor type, pathological type and FIGO stage (p>0.05). There was a significant negative correlation between the expression of miR-222 and the survival of patients with uterine cancer. In conclusion, the expression of miR-222 in uterine cancer tissues was significantly upregulated compared with that in adjacent tissues. The expression level of miR-222 was significantly increased with the increase of degree of tumor differentiation. The expression of miR-222 in uterine cancer tissue was not significantly correlated with patients' age, tumor size, gross tumor type, pathological type and FIGO stage. There was a significant negative correlation between the expression of miR-222 and the survival of patients with uterine cancer. It is expected that miR-222 will be an indicator and target for the treatment and prognosis of uterine cancer.

Introduction

Uterine cancer is the second most common malignancy in females and the incidence of this disease is only lower than that of breast cancer (1). According to a report released by the International Agency for Research on Cancer, >300,000 women die from uterine cancer each year, and >80% of them are from developing countries (2). In recent years, the incidence of uterine cancer shows an increasing trend in developing countries, especially in young women, incidence of this disease increases by 3% every year (3). So far, the mechanism of uterine cancer has not been completely elucidated. Therefore, the development of new biomarkers and effective treatment targets is the key to further improve the prognosis of uterine cancer. miRNAs are a class of highly conserved endogenous regulatory RNA molecules with a length of 18-26 bp. miRNAs bind to mRNA molecules transcribed from target genes and inhibit the its translation, ultimately regulating the expression of target genes (3,4). Many miRNAs, such as miR-16, miR-155 and miR-223, were upregulated in uterine cancer tissues (5), expression of some other miRNAs, such as miR-143 and miR-145, decreased in uterine cancer tissues (6), indicating that miRNAs may be key players in uterine cancer. miR-222 is highly expressed in a variety of tumors, including breast (7), bladder (8), colon (9), glioblastoma (10), and pancreatic cancer (11). However, the role of miR-222 in uterine cancer is still unclear. Therefore, in this study, the expression of miR-222 in uterine cancer and adjacent tissues was detected by stem-loop RT-PCR to investigate the relationship between miR-222 expression and clinicopathological features of this disease, so as to explore the role of miR-222 in the occurrence and development of uterine cancer and its clinical significance.

Patients and methods

Patients

Experimental data. A total of 66 patients with uterine cancer diagnosed by gynecological and pathological examination in Dongying People's Hospital (Dongying, China) were enrolled from March 2014 to October 2016. During surgical resection, uterine cancer and adjacent tissues were collected. Ages of patients ranged from 33 to 75 years. Among those patients, 27 patients had tumors <4 cm in diameter and the remaining patients all had a tumor diameter ≥4 cm. No patients received radiotherapy or chemotherapy before admission. Uterine cancer histopathological types: squamous cell carcinoma in 53 cases, adenocarcinoma in 9 cases, adenosquamous carcinoma in 4 cases. Uterine cancer tissue differentiation degree: 9 cases in grade I, 19 cases in grade II and 38 cases in grade III. FIGO stage: 6 cases in stage I, 25 cases in...
stage II, 18 cases in stage III and 17 cases in stage IV. All patients or their families signed informed consent. This study was approved by the Ethics Committee of Dongying People’s Hospital (Dongying, China).

Reagents and instruments. Tissue total RNA extraction kit (BioLabs Technology Co., Ltd., Beijing, China), miRNA reverse transcription kit (GeneCopoeia, Inc., Rockville, MD, USA), fluorescence quantitative PCR kit SYBR-Green (Huaxia Yuanyang Technology Co., Ltd., Beijing, China), urea (Healthdream Biological Technology Co., Ltd., Wuhan, China), ABI 7500 fluorescence quantitative PCR instrument (Thermo Fisher Scientific, Inc., Waltham, MA, USA), quantitative spectrophotometer (Jiang Xue Technology Co., Ltd., Chongqing, China).

Method

miR-222 expression analysis. Total RNA was extracted according to the manufacturer’s instructions, and A260/A280 ratio was measured using a quantitative spectrophotometer. Total RNA was reverse transcribed into cDNA in accordance with the instructions of miRNA reverse transcription kit. Reverse transcription system: 1 µg total RNA, 50 µM stem-loop RT primer, 2 U RNase inhibitor, 5 U M-MLV reverse transcriptase, and 0.5 µM dNTPs. Reaction conditions: 16˚C for 30 min, 42˚C for 30 min and 75˚C for 15 min. All cDNA samples were stored at -20˚C. This experiment was performed 3 times (Table I).

RT-qPCR reaction system (15 µl): 1 µl cDNA, 1X SYBR-Green I Mastermix, 0.5 µM miRNA specific forward primer, 0.5 µM universal reverse primer. Reaction conditions: 94˚C for 10 min, followed by 40 cycles of 95˚C for 15 sec, 60˚C for 60 sec, and 72˚C for 30 sec. With let-7a as endogenous control (12), the relative expression of miRNA was calculated automatically by RT-PCR instrument.

Analysis of the specificity of miR-222 stem-loop RT-PCR. A total of 5 µg total RNA was used to isolate low molecular weight RNAs. After denaturing by 15% urea solution, miRNA precursor and mature miRNA were then separated by 8% PAGE. Stem-loop RT-PCR was then performed to detect miR-222. Reaction volume was 20 µl. First, 2 µg of total RNA, 1 µl of RT primer (stem-loop primer) and 1 µl of dNTPs were mixed, and DEPC water was added to make a volume of 14 µl. After denaturation at 65˚C for 5 min, in the produced was kept on ice. Then 1 µl of reverse transcriptase AMV, 4 µl of buffer and 1 µl of RNase inhibitor were added. Reaction conditions were: 16˚C for 30 min, followed by 60 cycles of 20˚C for 30 sec, 42˚C for 30 sec and 50˚C for 1 sec, and 85˚C for 10 min.

Statistical analysis. Data were analyzed using SPSS 19.0 software (Beijing Xinmei Jiahong Technology Co., Ltd., Beijing, China). Measurement data were expressed as mean ± standard deviation, ANOVA was used for multiple group comparisons and the post hoc test was Dunnett’s test. Survival analysis was performed using GraphPad Prism 5 with α=0.05 as standard.

Results

Establishment of stem-loop RT-PCR detection method. The product of miRNA amplification by stem-loop RT-PCR showed a single band after 8% PAGE. So stem-loop RT-PCR method can specifically amplify miR-222 (Fig. 1). As shown in Fig. 2, after 8% PAGE, gray values of the bands derived from PCR reaction with 22 or 30 cycles were similar. PCR with 30 cycles provided a faint band, while PCR
miR-222 expression in uterine cancer and adjacent tissues. With let-7a as endogenous control, the relative expression levels of miR-222 in adjacent and uterine cancer tissues were 0.275±0.094 and 0.953±0.183, respectively. The expression level of miR-222 in adjacent tissues was significantly lower than that in uterine cancer tissues. The difference was statistically significant (p<0.05) (Fig. 3).

Correlation between miR-222 expression and a variety of clinicopathological features of uterine cancer.

| Clinicopathological features | Cases | miR-222 expression | P-value |
|-----------------------------|-------|--------------------|---------|
| Age (years)                 |       |                    |         |
| <40                         | 17    | 0.394±0.074        | 0.916   |
| 40-60                       | 21    | 0.371±0.068        |         |
| >60                         | 28    | 0.474±0.085        |         |
| Tumor size (cm)             |       |                    |         |
| <4                          | 27    | 0.527±0.093        | 0.617   |
| ≥4                          | 39    | 0.416±0.078        |         |
| Gross type                  |       |                    |         |
| Exogenous type              | 32    | 0.371±0.064        | 0.563   |
| Endogenous type             | 19    | 0.398±0.069        |         |
| Ulcer type                  | 11    | 0.474±0.086        |         |
| Neck type                   | 4     | 0.973±0.184        |         |
| Tissue differentiation      |       |                    |         |
| Large cell keratinizing (I) | 9     | 0.214±0.047        | 0.001   |
| Non-Keratinizing type (II)  | 19    | 0.289±0.051        |         |
| Small cell type (III)       | 38    | 0.656±0.117        |         |
| Pathological type           |       |                    |         |
| Squamous cell carcinoma     | 53    | 0.427±0.082        | 0.628   |
| Adenocarcinoma              | 9     | 0.416±0.079        |         |
| Adenosquamous carcinoma     | 4     | 0.398±0.077        |         |
| FIGO stage                  |       |                    |         |
| Stage I                     | 6     | 0.234±0.049        | 0.284   |
| Stage II                    | 25    | 0.425±0.082        |         |
| Stage III                   | 18    | 0.419±0.084        |         |
| Stage IV                    | 17    | 0.427±0.087        |         |

Correlation between miR-222 expression and prognosis. Follow-up study of 66 uterine cancer patients showed that the median survival time of miR-222 high expression uterine cancer patients was 21.4±0.8 months, while the median survival time of miR-222 low expression uterine cancer patients was 44.9±1.7 months. The expression level of miR-222 was significantly negatively correlated with the survival of uterine cancer patients (p<0.05) (Fig. 4).
Discussion

Uterine cancer is the second most common malignancy in women, and its incidence is only lower than that of breast cancer (13). However, pathogenesis of uterine cancer has not been fully understood, leading to poor treatment outcomes as well as high recurrence and mortality rate (14). As a class of highly conserved endogenous regulatory RNAs, miRNAs bind to mRNAs transcribed from target genes to inhibit further translation, thereby regulating the expression of target genes and participating in a series of physiological and pathological processes (15). miRNA can play a role as oncogene or tumor suppressor gene in the occurrence and development of a tumor (16).

Analysis of the expression pattern of miRNAs in invasive cervical squamous cell carcinoma showed that most miRNAs were upregulated and only two were downregulated (16). The expression level of miR-127 is significantly correlated with lymph node metastasis (17). Some scholars found that in colon cancer tissues, miR-143 and miR-145 expression were significantly downregulated (18,19). In addition, abnormal expression of a large number of miRNAs in solid tumors was observed, and most miRNAs, such as miR-21, miR-92 and miR-155, were usually upregulated (20,21).

In recent years, studies have shown that the expression level of miR-222 is increased to varying degrees in tumor tissue or tumor cell lines of different types of cancer (22,23). miR-222 is involved in the occurrence and development of a variety of cancers, such as bladder cancer (24), prostate cancer (25), and melanoma (26). Among these cancers, target genes are usually tumor suppressor genes or pre-apoptotic factors. miR-222 inhibits cell apoptosis and participates in the occurrence and development of tumor through the regulation of expression of its target genes (23). Results of this study showed that the stem-loop RT-PCR can specifically amplify miRNA. miR-222 was significantly upregulated in uterine cancer tissue, suggesting that miR-222 may be involved in the occurrence and development of uterine cancer. It has been reported that miR-222 can regulate the expression of PTEN to affect the radiosensitivity, cell growth and invasion of gastric cancer SGC7901 cells. When miR-222 was downregulated, the malignant behavior of SGC7901 cells was significantly inhibited, suggesting that miR-222 may play a role as oncogene in gastric cancer (27). Different expression levels of miRNA were observed in uterus cancer tissues with the different differentiation degrees. The expression level of miR-222 in grade III uterine cancer was obviously higher than that in grade I and II. The expression level of miR-222 was increased with the increased degree of malignancy. Therefore, we speculate that miR-222 expression upregulation in uterine cancer may silence downstream tumor suppressor genes such as p27 (28), p57 (29) and Bmf (30). In addition, the expression level of miR-222 was negatively correlated with the survival time of patients with uterine cancer, suggesting that the expression of miR-222 in uterine cancer may serve as an indicator for the prognosis of this disease.

In conclusion, upregulated expression of miR-222 in uterine cancer may play an important role in the occurrence and development of uterine cancer. Our future studies will focus on the function of target genes of miR-222 to identify new targets for the treatment of uterine cancer.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

XN conceived and designed the study, and drafted the report. XN and HT collected, analyzed and interpreted the experimental data, and revised the manuscript critically for important intellectual content. Both authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Dongying People's Hospital (Dongying, China). Signed written informed consents were obtained from the patients or the guardians.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Kowalewska M, Bakula-Zalewska E, Chechlińska M, Goryca K, Nasirowska-Gutmejer A, Danskia-Bidzinska A and Bidzinski M: MicroRNAs in uterine sarcomas and mixed epithelial-mesenchymal uterine tumors: A preliminary report. Tumour Biol 34: 2153-2160, 2013.
2. Peralta-Zaragoza O, Deas J, Meneses-Acosta A, De la O-Gómez F, Fernández-Tilapa G, Gómez-Cerón C, Benítez-Boisseaneau O, Burgute-García A, Torres-Poveda K, Bermúdez-Morales VH, et al: Relevance of miR-21 in regulation of tumor suppressor gene PTEN in human cervical cancer cells. BMC Cancer 16: 215, 2016.
3. Fang H, Shuang D, Yi Z, Sheng H and Liu Y: Up-regulated microRNA-155 expression is associated with poor prognosis in cervical cancer patients. Biomed Pharmacother 83: 64-69, 2016.
4. Pang H and Yue X: MiR-205 serves as a prognostic factor and suppresses proliferation and invasion by targeting insulin-like growth factor receptor 1 in human cervical cancer. Tumour Biol 39: 1010428317701308, 2017.
5. Sun Y, Zhang B, Cheng J, Wu Y, Xing F, Wang Y, Wang Q and Qiu J: MicroRNA-222 promotes the proliferation and migration of cervical cancer cells. Clin Invest Med 37: E131, 2014.
6. Sun L, Jiang R, Li J, Wang B, Ma C, Lv Y and Mu N: MicroRNA-425-5p is a potential prognostic biomarker for cervical cancer. Ann Clin Biochem 54: 127-133, 2017.
7. Liu P, Sun M, Jiang W, Zhao J, Liang C and Zhang H: Identification of targets of miRNA-221 and miRNA-222 in fulvestrant-resistant breast cancer. Oncol Lett 12: 3882-3888, 2016.
8. Zhang DQ, Zhou CK, Jiang XW, Chen J and Shi BK: Increased expression of miR-222 is associated with poor prognosis in bladder cancer. World J Surg Oncol 12: 241, 2014.
19. Ahmed FE, Amed NC, Vos PW, Bonnerup C, Atkins JC, Casey M, Nuovo GJ, Naziri W, Wiley JE and Allison RR: Diagnostic microRNA markers to screen for sporadic human colon cancer in blood. Cancer Genomics Proteomics 9: 179-192, 2012.

20. Lorimer IA: Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 8: 2685, 2009.

21. Zhao Y, Wang Y, Yang Y, Liu J, Song Y, Cao Y, Chen X, Yang W, Wang F, Gao J, et al: MicroRNA-222 controls human pancreatic cancer cell line capan-2 proliferation by p57 targeting. J Cancer 6: 1230-1235, 2015.

22. Peltier HJ and Latham GJ: Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference miRNA targets in normal and carcinous human solid tissues. RNA 14: 844-852, 2008.

23. Dong Y, Si JW, Li WT, Liang L, Zhao J, Zhou M, Li D and Li T: miR-200a/miR-141 and miR-205 upregulation might be associated with hormone receptor status and prognosis in endometrial carcinomas. Int J Clin Exp Pathol 8: 2864-2875, 2015.

24. Tseng JH, Bisogna M, Hoang LN, Œlvera N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Levine DA and Jelinic P: miR-200c-driven mesenchymal-to-epithelial transition is a therapeutic target in uterine carcinosarcomas. Sci Rep 7: 3614, 2017.

25. Sun H, Xin J, Lu Z, Wang N, Liu N and Guo Q: Potential molecular mechanisms for improved prognosis and outcome with neoadjuvant chemotherapy prior to laparoscopic radical hysterectomy for patients with cervical cancer. Cell Physiol Biochem 32: 1528-1540, 2013.

26. Xiong X, Cheng J, Liu X, Tang S and Luo X: Correlation analysis between miR-124 rs531564 polymorphisms and susceptibility to endometrial carcinoma via targeting ER alpha. Oncol Rep 37: 8931-8940, 2016.

27. Liu J: Reduced expression of miR-503 is associated with poor prognosis in cervical cancer. Eur Rev Med Pharmacol Sci 19: 4081-4085, 2015.

28. Li W, Liang J, Zhang Z, Lou H, Zhao L, Xu Y and Ou R: MicroRNA-329-3p targets MAPK1 to suppress cell proliferation, migration and invasion in cervical cancer. Oncol Rep 37: 2743-2750, 2017.

29. Zhang X, Dong Y, Ti H, Zhao J, Wang Y, Li T and Zhang B: Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas. Hum Pathol 44: 2571-2580, 2013.

30. Sun J, Chu H, Ji J, Huo G, Song Q and Zhang X: Long non-coding RNA HOTAIR modulates HLA-G expression by absorbing miR-148a in human cervical cancer. Int J Oncol 49: 943-952, 2016.

31. Shen SN, Wang LF, Jia YF, Hao YQ, Zhang L and Wang H: Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer. Diagn Pathol 8: 69, 2013.

32. Azizmohammadi S, Safari A, Azizmohammadi S, Kaghazian M, Sadrkhanlo M, Yahaghi E, Farshgar R and Seifoleslami M: Molecular identification of miR-145 and miR-9 expression level as prognostic biomarkers for early-stage cervical cancer detection. QJM 110: 11-15, 2017.

33. Chun-Zhi Z., Lei H, An-Ling Z., Yan-Chao F., Xiao Y., Guang-Xiu W., Zhi-Fan J., Pei-Yu P., Qing-Yu Z. and Chun-Sheng K.: MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 10: 367, 2010.

34. Wang Y, Zeng J, Pan J, Geng X, Liu Y, Wu J, Song P, Wang Y, Jia J and Wang L: MicroRNA-200c is involved in proliferation of gastric cancer by directly repressing p27Kip1. Cell Death Dis 7: e2109, 2016.

35. Zhang E, He X, Yin D, Han L, Qiu M, Xu T, Xia R, Xu L, Yin R and De W: Increased expression of long noncoding RNA TUG1 predicts a poor prognosis of gastric cancer and regulates cell proliferation by epigenetically silencing of p57. Cell Death Dis 7: e2109, 2016.

36. Zuo L, Cheng X, Shi J, Jiacheng L, Chen G, Jin H, Liu AB, Pyo H, Ye J, Zhu Y, et al: Crosstalk between bone marrow-derived myofibroblasts and gastric cancer cells regulates cancer stemness and promotes tumorigenesis. Oncogene 35: 5388-5399, 2016.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.